Gossamer Bio, Inc. — Form 8-K
Filed September 11, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Gossamer Bio completed a 1-for-80 reverse stock split effective September 10, 2026, automatically combining every 80 shares into 1 share. Authorized common shares reduced from 4 billion to 50 million; total authorized capital stock reduced from 4.07 billion to 120 million. The split aims to restore Nasdaq compliance (stock price must reach $1.00+ for 10 consecutive trading days by October 5, 2026). Convertible notes, warrants, and equity awards were proportionately adjusted; stockholder ownership percentages remain unchanged.
Why this rating
Reverse split is routine capital structure adjustment with no economic change to shareholders. Regaining Nasdaq compliance is necessary but uncertain; failure poses delisting risk. Material only if stock fails to recover price target.
See more from September 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.